Hyperuricemia (High Uric Acid) Management Protocol

Hyperuricemia is elevated uric acid levels in the blood (typically >6.8 mg/dL in men, >6 mg/dL in women). Uric acid is produced when the body breaks down purines (found in certain foods and drinks). High levels can lead to gout (painful crystal deposits in joints) and kidney stones.

WHY URIC ACID RISES:

•Overproduction: High purine diet, genetic factors

•Underexcretion: Most common cause (kidneys don't excrete enough)

•Combined: Both mechanisms together

RISK FACTORS:

•Diet high in purines (red meat, organ meats, shellfish)

•Alcohol, especially beer

•Fructose and sugary drinks

•Obesity

•Kidney disease

•Certain medications (diuretics, low-dose aspirin)

•Metabolic syndrome

CONSEQUENCES:

•Gout attacks

•Kidney stones

•May contribute to cardiovascular and kidney disease

DIETARY MODIFICATIONS:

•Reduce high-purine foods

•Limit alcohol (especially beer)

•Reduce fructose/sugar intake

•Stay well hydrated

•Include low-fat dairy (protective)

•Coffee may be protective

WHEN MEDICATION IS NEEDED:

•Recurrent gout attacks

•Tophi (uric acid deposits)

•Kidney stones

•Very high levels with complications

* Vitamin C can lower uric acid by about 0.5 mg/dL at higher doses.

* Tart cherry has shown uric acid-lowering effects and gout prevention.

* Quercetin may inhibit the enzyme that produces uric acid.

Expected timeline: Dietary and supplement interventions may take 4-8 weeks to show measurable effects on uric acid levels.

Clinical Perspective

Hyperuricemia: Serum uric acid >6.8 mg/dL (supersaturation point). Causes: underexcretion (90%), overproduction (10%), or both. Associated conditions: gout, nephrolithiasis, CKD, metabolic syndrome, CVD. Treatment threshold controversial for asymptomatic hyperuricemia.

CRITICAL: Treat hyperuricemia when symptomatic (gout, stones). Asymptomatic hyperuricemia treatment remains controversial - individualized risk assessment. Lifestyle modifications are first-line. Medications (allopurinol, febuxostat, probenecid) for recurrent gout or complications. Target serum urate <6 mg/dL for gout. Supplements provide modest adjunctive benefit - not substitutes for medications when indicated.

* Vitamin C (B-grade): Uricosuric. Meta-analysis: (PMID: 23075608). 500-1500mg daily. ~0.5 mg/dL reduction.

* Tart Cherry (B-grade): Xanthine oxidase inhibition. Review: (PMID: 28212056). 240-480ml juice or 500-1000mg extract daily.

* Quercetin (C-grade): XO inhibition. Review: (PMID: 26729615). 500mg twice daily.

* Folic Acid (C-grade): XO inhibition. Systematic review: (PMID: 27450775). 5mg daily. Higher doses needed for effect.

* Celery Seed (C-grade): Traditional use. Review: (PMID: 26182896). 75-150mg twice daily.

* Omega-3 (C-grade): Anti-inflammatory. Review: (PMID: 27840029). 2g EPA+DHA daily.

* Bromelain (C-grade): Anti-inflammatory. Review: (PMID: 22426836). 500-1000mg daily.

Assessment targets: Serum uric acid, gout flare frequency, renal function, kidney stones, metabolic parameters.

Protocol notes: Diet: limit purines (organ meats, game, sardines, anchovies, shellfish), fructose, alcohol (especially beer). Hydration: 2-3L daily prevents stone formation. Coffee: epidemiological association with lower uric acid. Low-fat dairy: protective. Weight loss: reduces uric acid significantly. Medications: xanthine oxidase inhibitors (allopurinol, febuxostat) reduce production; uricosurics (probenecid) increase excretion. Target: <6 mg/dL for gout patients, <5 mg/dL if tophi. Flare prophylaxis: colchicine or NSAID when starting ULT. Triggers: avoid crash diets, dehydration, fasting. Comorbidities: assess and manage CVD risk factors, CKD, metabolic syndrome. ABCG2/SLC2A9: genetic variants affect urate transport. Lesinurad: URAT1 inhibitor; used with XO inhibitor. Pegloticase: recombinant uricase for refractory gout.

View All Protocols